Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Contract Development Services, Small Molecules, Contract Manufacturing Services

A Foggy Forecast?

I was very interested to read Stephanie Sutton’s editorial comment, “Bringing Down the House” in the June issue of The Medicine Maker (1). The editorial points out the challenges that pharma and biotech companies of all sizes face when it comes to forecasting demand for products. Some inaccurate forecasts have resulted in manufacturing plants being built, then standing idle, and eventually being demolished without ever producing a single dose, such as Sanofi’s Montpellier facility in France. What an incredible waste of time, talent and resources that could be directed to new drug development.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Michael Lehmann

Michael Lehmann is President, Global Sales & Marketing, Pharmaceutical Services, at Thermo Fisher Scientific, Durham, NC, USA.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register